GIFT Nifty signals positive start; US tariffs, earnings in focus

Indian markets are acceptable for a cautious yet affirmative commencement connected Wednesday, with GIFT Nifty rising 50 points to 23,180. Investors stay watchful amid ongoing commercialized tensions, anemic home earnings, and PM Modi’s important US visit, wherever discussions with Donald Trump could easiness tariff concerns.

Technical outlook: Lower lows awesome caution

Nifty continues to show a bearish signifier with little tops and bottoms. Analysts foretell a imaginable dip beneath the January plaything debased of 22,786, portion immoderate rebound is expected to look beardown absorption astatine 23,200 levels. Meanwhile, India VIX jumped 3 per cent to 14.87, reflecting rising marketplace volatility.

Global cues: Mixed signals from US and Asia

Wall Street closed mixed, with S&P 500 down 0.01 per cent and Nasdaq slipping 0.21 per cent, portion Dow gained 0.08 per cent. Asian equities showed a mixed trend—Japanese stocks advanced, but Australia’s S&P/ASX 200 remained flat. Hang Seng futures roseate 1 per cent, indicating a imaginable rebound successful Hong Kong stocks.

Rupee, FII action, and F&O prohibition list

The rupee gained 61 paise to 86.84 against the US dollar amid heightened planetary commercialized concerns. FIIs turned nett sellers, offloading Rs 4,486 crore worthy of shares, portion DIIs provided immoderate cushion by purchasing Rs 4,002 crore. Manappuram remains successful the F&O prohibition database aft breaching the 95 per cent market-wide presumption limit.

Gold retreat arsenic US ostentation information looms

Gold prices eased aft touching an all-time high, arsenic investors displacement absorption to the upcoming US ostentation report, which could dictate the Federal Reserve’s adjacent complaint move.

With cardinal economical indicators and commercialized negotiations connected the radar, markets are apt to enactment volatile successful the adjacent term. Traders should ticker retired for imaginable breakouts and downside risks.